Skip to main content
. 2024 Oct 21;30(39):4295–4304. doi: 10.3748/wjg.v30.i39.4295

Table 1.

Demographic and clinical data of patients

Variables
500 mg bid (n = 73)
500 mg tid (n = 74)
750 mg bid (n = 71)
P value
Age, mean ± SD 49.2 ± 12.0 50.2 ± 13.9 46.6 ± 15.8 0.348
Age range (years) 20-72 23-72 22-77
Age, ≤ 50 years 36 35 40 0.523
Sex, male/female 41/32 39/35 40/31 0.899
Family history of gastric cancer 1 2 1 1.000
NSAIDS 2 3 0 0.375
Probiotics 7 2 3 0.202
Smoking 15 16 15 1.000
Alcohol drinking 10 14 13 0.689
Hypertension 17 17 15 0.958
Diabetes 5 6 3 0.694
Hyperlipidemia 1 3 1 0.623
Endoscopy diagnosis 0.600
    Gastritis 49 42 36
    Ulcer 14 7 9
    Unknown 10 25 26
Intestinal metaplasia 0.325
    No 40 27 22
    Yes 23 22 23
    Unknown 10 25 26
Treatment times < 0.001
    1 60 42 16
    2 8 27 39
    ≥ 3 5 5 16
    Rescue therapy1 13 32 55
PPI < 0.001
    Omeprazole 2 5 27
    Rabeprazole 66 63 37
    Pantoprazole 1 5 1
    Vonoprazan 4 1 6
Bismuth < 0.001
    Bismuth potassium citrate 4 27 37
    Colloidal bismuth pectin 69 47 34
1

Rescue therapy was defined as patients who had received eradication therapy once or more but failed.

P values were from two-sided comparisons of the differences between the three groups. 500 mg bid: Tetracycline twice daily; 500 mg tid: Tetracycline three times daily; 750 mg bid: Tetracycline twice daily; NSAIDS: Nonsteroidal anti-inflammatory drugs; PPI: Proton pump inhibitor.